{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T21:47:12Z","timestamp":1779313632489,"version":"3.51.4"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Epidemiology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.canep.2026.103059","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T03:51:12Z","timestamp":1774669872000},"page":"103059","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Association between pioglitazone use and prostate cancer in patients with type 2 diabetes: A retrospective cohort study"],"prefix":"10.1016","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7420-1572","authenticated-orcid":false,"given":"Shih-Wei","family":"Lai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuan-Fu","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canep.2026.103059_bib1","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1002\/cncr.35444","article-title":"Global cancer statistics 2022: the report offers a view on disparities in the incidence and mortality of cancer by sex and region worldwide and on the areas needing attention","volume":"130","author":"Nierengarten","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.canep.2026.103059_bib2","unstructured":"Institute N.C.. Surveillance, Epidemiology, and End Results (SEER) Program. [cited on September 2025, English version].doi:"},{"key":"10.1016\/j.canep.2026.103059_bib3","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMra041001","article-title":"Thiazolidinediones","volume":"351","author":"Yki-J\u00e4rvinen","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canep.2026.103059_bib4","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1517\/14656566.9.7.1087","article-title":"Pleiotropic effects of thiazolidinediones","volume":"9","author":"Rizos","year":"2008","journal-title":"Expert Opin. Pharm."},{"key":"10.1016\/j.canep.2026.103059_bib5","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jama.2015.7996","article-title":"Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes","volume":"314","author":"Lewis","year":"2015","journal-title":"Jama"},{"key":"10.1016\/j.canep.2026.103059_bib6","doi-asserted-by":"crossref","first-page":"i3903","DOI":"10.1136\/bmj.i3903","article-title":"Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries","volume":"354","author":"Korhonen","year":"2016","journal-title":"Bmj"},{"key":"10.1016\/j.canep.2026.103059_bib7","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/dom.13049","article-title":"Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes","volume":"20","author":"Garry","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.canep.2026.103059_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2016-000303","article-title":"Evaluation of exposure to pioglitazone and risk of prostate cancer: a nested case-control study","volume":"4","author":"Boxall","year":"2016","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"10.1016\/j.canep.2026.103059_bib9","doi-asserted-by":"crossref","first-page":"119","DOI":"10.5534\/wjmh.210157","article-title":"Pioglitazone and prostate cancer risk in taiwanese male patients with type 2 diabetes: a retrospective cohort study","volume":"41","author":"Tseng","year":"2023","journal-title":"World J. Mens. Health"},{"key":"10.1016\/j.canep.2026.103059_bib10","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12943-025-02320-y","article-title":"The anti-diabetic PPAR\u03b3 agonist Pioglitazone inhibits cell proliferation and induces metabolic reprogramming in prostate cancer","volume":"24","author":"Atas","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canep.2026.103059_bib11","unstructured":"TriNetX. Real-world data. \u3008https:\/\/trinetx.com\/real-world-data\/\u3009. Accessed 2025 Aug 1."},{"key":"10.1016\/j.canep.2026.103059_bib12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.annepidem.2023.05.004","article-title":"The application of lag times in cancer pharmacoepidemiology: a narrative review","volume":"84","author":"Hicks","year":"2023","journal-title":"Ann. Epidemiol."},{"key":"10.1016\/j.canep.2026.103059_bib13","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/bcpt.12946","article-title":"Considerations for pharmacoepidemiological studies of drug-cancer associations","volume":"122","author":"Potteg\u00e5rd","year":"2018","journal-title":"Basic Clin. Pharm. Toxicol."}],"container-title":["Cancer Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782126000743?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782126000743?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T11:14:23Z","timestamp":1779016463000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877782126000743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":13,"alternative-id":["S1877782126000743"],"URL":"https:\/\/doi.org\/10.1016\/j.canep.2026.103059","relation":{},"ISSN":["1877-7821"],"issn-type":[{"value":"1877-7821","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between pioglitazone use and prostate cancer in patients with type 2 diabetes: A retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Cancer Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canep.2026.103059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103059"}}